Pre-16S and 16S rRNA Measurements from Tuberculosis Treatment Trial

A retrospective study of 19 patients from the HIGHRIF2 clinical trial (NCT00760149) provides gene expression data for monitoring tuberculosis treatment. Evelin Dombay created this dataset, which includes multiplex RT-qPCR measurements of pre-16S rRNA and 16S rRNA levels from sequential patient samples during a 36-day treatment period. The data supports analysis of bacterial burden and metabolic activity changes under different rifampicin doses.

Use Cases

• Model the double exponential decay curve of pre-16S rRNA relative gene expression (R² = 0.996) to compare drug regimen efficacy.
• Analyze the correlation between cycle threshold (Cq) value slopes (0.404 for pre-16S, 0.212 for 16S) and daily reduction in bacterial load (-0.072 log10 CFU ml⁻¹/day).
• Compare maximum suppression (Rmin=1.694) and time to suppression (T=9.78 days) parameters for 1200 mg rifampicin therapy against other doses.
• Use pre-16S rRNA and 16S rRNA measurements as combined markers to distinguish bacterial metabolic activity from total burden during antibiotic exposure.

Strengths

• Data from a controlled Phase II clinical trial (HIGHRIF2, NCT00760149) with defined protocols.
• Includes specific model fit metrics (R² = 0.996) and statistical significance values (P<0.0001).
• Provides longitudinal measurements over a 36-day treatment window for 19 patients.

Limitations

• Very small sample size of 19 patients limits statistical power and generalizability.
• Data is presented in a PDF report (338.2 KB), likely requiring extraction for computational analysis.
• Retrospective study design from a single trial may introduce selection bias.

Provenance

Source

Figshare, authored by Evelin Dombay.

Collection Method

Multiplex reverse transcriptase quantitative PCR (RT-qPCR) assay on sequential patient samples.

Time Range

Treatment period covering the initial 36 days; clinical trial active circa NCT00760149 registration.

Freshness

Last updated on the platform in April 2026, though the underlying clinical trial data is older.